Abstract
Reacquiring the target: A proteomic profiling approach has been used to show that aldehyde dehydrogenase 1 may be an additional or alternative target of duocarmycin. Selective inhibition of this enzyme in lung cancer cells explains the antitumor activity of duocarmycin analogues (see scheme).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
